Press release from Companies
Publicerat: 2021-03-11 17:43:07
Cessatech A/S ("Cessatech" or the "Company") hereby publishes its annual report for the fiscal year 2020. The annual report including the auditor’s report is attached as a pdf. The report is also available on Cessatech’s website www.cessatech.com under ‘Fillings & Reports’.
Full year 2020 (6 April – 31 December):
Established the company, the legal entity (6. APR)
For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is expected to enter late stage clinical development in 2021.